Advertisement

Ads Placeholder
Loading...

Zylox-Tonbridge Medical Technology Co., Ltd.

2190.HKHKSE
Healthcare
Medical - Devices
HK$23.70
HK$-0.42(-1.74%)
Hong Kong Market is Open • 12:38

Zylox-Tonbridge Medical Technology Co., Ltd. Fundamental Analysis

Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK) shows moderate financial fundamentals with a PE ratio of 27.44, profit margin of 23.12%, and ROE of 7.59%. The company generates $1.1B in annual revenue with strong year-over-year growth of 48.27%.

Key Strengths

Cash Position22.88%
PEG Ratio0.54
Current Ratio5.98

Areas of Concern

ROE7.59%
We analyze 2190.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 72.4/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B
72.4/100

We analyze 2190.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

2190.HK struggles to generate sufficient returns from assets.

ROA > 10%
6.78%

Valuation Score

Moderate

2190.HK shows balanced valuation metrics.

PE < 25
27.44
PEG Ratio < 2
0.54

Growth Score

Moderate

2190.HK shows steady but slowing expansion.

Revenue Growth > 5%
48.27%
EPS Growth > 10%
2.29%

Financial Health Score

Excellent

2190.HK maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
5.98

Profitability Score

Moderate

2190.HK maintains healthy but balanced margins.

ROE > 15%
7.59%
Net Margin ≥ 15%
23.12%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is 2190.HK Expensive or Cheap?

P/E Ratio

2190.HK trades at 27.44 times earnings. This indicates a fair valuation.

27.44

PEG Ratio

When adjusting for growth, 2190.HK's PEG of 0.54 indicates potential undervaluation.

0.54

Price to Book

The market values Zylox-Tonbridge Medical Technology Co., Ltd. at 2.06 times its book value. This may indicate undervaluation.

2.06

EV/EBITDA

Enterprise value stands at 33.59 times EBITDA. This signals the market has high growth expectations.

33.59

How Well Does 2190.HK Make Money?

Net Profit Margin

For every $100 in sales, Zylox-Tonbridge Medical Technology Co., Ltd. keeps $23.12 as profit after all expenses.

23.12%

Operating Margin

Core operations generate 18.92 in profit for every $100 in revenue, before interest and taxes.

18.92%

ROE

Management delivers $7.59 in profit for every $100 of shareholder equity.

7.59%

ROA

Zylox-Tonbridge Medical Technology Co., Ltd. generates $6.78 in profit for every $100 in assets, demonstrating efficient asset deployment.

6.78%

Following the Money - Real Cash Generation

Operating Cash Flow

Zylox-Tonbridge Medical Technology Co., Ltd. generates limited operating cash flow of $70.19M, signaling weaker underlying cash strength.

$70.19M

Free Cash Flow

Zylox-Tonbridge Medical Technology Co., Ltd. generates weak or negative free cash flow of $608.29K, restricting financial flexibility.

$608.29K

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

2190.HK converts 0.01% of its market value into free cash.

0.01%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

27.44

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.54

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.06

vs 25 benchmark

P/S Ratio

Price to sales ratio

6.36

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.98

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.08

vs 25 benchmark

ROA

Return on assets percentage

0.07

vs 25 benchmark

ROCE

Return on capital employed

0.06

vs 25 benchmark

How 2190.HK Stacks Against Its Sector Peers

Metric2190.HK ValueSector AveragePerformance
P/E Ratio27.4428.54 Neutral
ROE7.59%738.00% Weak
Net Margin23.12%-43982.00% (disorted) Strong
Debt/Equity0.020.34 Strong (Low Leverage)
Current Ratio5.982806.01 Strong Liquidity
ROA6.78%-14624.00% (disorted) Weak

2190.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Zylox-Tonbridge Medical Technology Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

15817.67%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

254.85%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

427.96%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ